Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Anlotinib in Platinum-Resistant Clear Cell Ovarian Cancer
NCT05130515Phase 2Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, anlotinib in ovarian clear cell carcinoma (OCCC), sponsored by Sun Yat-sen Memorial Hospital. Started Dec 2021; status: completed.
02
Drugs
niraparibanlotinib
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT05130515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130515.